Park, Jongjin
Yoon, Jiyoung
Kwon, Daekee
Han, Mi-Jung
Choi, Sunmee
Park, Slki
Lee, Junghyuk
Lee, Kiwook
Lee, Jaehwan
Lee, Seunghee
Kang, Kyung-Sun
Choe, Sunghwa
Funding for this research was provided by:
CRISPR PLUS R&D program (2016GFRND-CP001)
Basic Science Research Program through the National Research Foundation of Korea (2020R1F1A1063608)
Article History
Received: 22 March 2021
Accepted: 19 July 2021
First Online: 10 August 2021
Change Date: 10 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-021-98186-3
Competing interests
: J.P. is an employee of Naturegenic, Inc., and J.Y., S.Choi., Ju.L., S.P., K.L., and Ja.L. are employees of G + FLAS Life Sciences. S.C., J.P., J.Y., Ju.L., and Ja.L. are inventors of patents and patent applications related to the CRISPR PLUS genome editing technologies. S.Choe. is a CEO of G + FLAS Life Sciences, Inc. K-S.K. is a founder and GVO (Global Vision Officer) of Kangstem Biotech Co., Ltd., D.K., M-J.H., S.L. is employees of Kangstem Biotech Co., Ltd. All other authors declare no conflicts of interests.